Adipokines Levels Are Associated with the Severity of Liver Disease in Patients with Alcoholic Cirrhosis
Overview
Authors
Affiliations
Aim: To investigate the adipokine levels of leptin, adiponectin, resistin, visfatin, retinol-binding protein 4 (RBP4), apelin in alcoholic liver cirrhosis (ALC).
Methods: Forty non-diabetic ALC patients [median age: 59 years, males: 35 (87.5%), Child-Pugh (CP) score: median 7 (5-12), CP A/B/C: 18/10/12, Model for End-stage Liver Disease (MELD): median 10 (6-25), follow-up: median 32.5 mo (10-43)] were prospectively included. The serum adipokine levels were estimated in duplicate by ELISA. Somatometric characteristics were assessed with tetrapolar bioelectrical impedance analysis. Pearson's rank correlation coefficient was used to assess possible associations with adipokine levels. Univariate and multivariate Cox regression analysis was used to determine independent predictors for overall survival.
Results: Body mass index: median 25.9 (range: 20.1-39.3), fat: 23.4% (7.6-42.1), fat mass: 17.8 (5.49-45.4), free fat mass: 56.1 (39.6-74.4), total body water (TBW): 40.6 (29.8-58.8). Leptin and visfatin levels were positively associated with fat mass (P < 0.001/P = 0.027, respectively) and RBP4 with TBW (P = 0.025). Median adiponectin levels were significantly higher in CPC compared to CPA (CPA: 7.99 ± 14.07, CPB: 7.66 ± 3.48, CPC: 25.73 ± 26.8, P = 0.04), whereas median RBP4 and apelin levels decreased across the spectrum of disease severity (P = 0.006/P = 0.034, respectively). Following adjustment for fat mass, visfatin and adiponectin levels were significantly increased from CPA to CPC (both P < 0.001), whereas an inverse correlation was observed for both RBP4 and apelin (both P < 0.001). In the multivariate Cox regression analysis, only MELD had an independent association with overall survival (HR = 1.53, 95%CI: 1.05-2.32; P = 0.029).
Conclusion: Adipokines are associated with deteriorating liver function in a complex manner in patients with alcoholic liver cirrhosis.
Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression.
Forte E, Sanders J, Pla I, Kanchustambham V, Hollas M, Huang C Mol Cell Proteomics. 2024; 23(12):100876.
PMID: 39521382 PMC: 11664408. DOI: 10.1016/j.mcpro.2024.100876.
Adiponectin as a biomarker in liver cirrhosis-A systematic review and meta-analysis.
Ismaiel A, Ciornolutchii V, Herrera T, Ismaiel M, Leucuta D, Popa S Eur J Clin Invest. 2024; 55(1):e14328.
PMID: 39487742 PMC: 11628646. DOI: 10.1111/eci.14328.
Pollmanns M, Pajaziti Q, Hohlstein P, Adams J, Abu Jhaisha S, Kabak E Biomedicines. 2024; 12(10).
PMID: 39457486 PMC: 11504267. DOI: 10.3390/biomedicines12102173.
Quetglas-Llabres M, Monserrat-Mesquida M, Bouzas C, Garcia S, Mateos D, Casares M Antioxidants (Basel). 2024; 13(7).
PMID: 39061823 PMC: 11273830. DOI: 10.3390/antiox13070754.
Optimised expression and purification of RBP4 and preparation of anti-RBP4 monoclonal antibody.
Li H, He X, Wen S, Yang L, Chen Q, Li Y FEBS Open Bio. 2021; 12(2):430-442.
PMID: 34889069 PMC: 8804599. DOI: 10.1002/2211-5463.13349.